The Kiniksa pipeline has the potential to treat a full spectrum of autoinflammatory & autoimmune diseases.
|Program & Mechanism||Indication||Preclin||Early Clinical||Mid Clinical||Pivotal||Mkt||Rights|
|KPL-914||Rare Inflammatory||MKT||Transfers to Kiniksa upon sBLA approval|
|Inflamm. Cardio||Mid-Clinical||Worldwide (excl. Middle East and North Africa)|
KPL-914 is an approved, subcutaneously-administered, cytokine trap that inhibits the signaling of two soluble cytokines. There are multiple diseases involving these cytokines where KPL-914 may provide benefit, the first of which is in a rare, inflammatory, cardiovascular disease where there are currently no approved therapies.
Inhibitor of a key growth factor for cells of myeloid lineage
Monoclonal antibody inhibitor of two inflammatory cytokines involved in Th2 response, pruritus, fibrosis and barrier dysfunction
Inhibitor of a key T-cell co-stimulatory mechanism important in the function of activated T-memory cells
Inhibitor of a central control node of T-cell-dependent, B-cell-mediated humoral adaptive immunity